We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

58 hedge funds and large institutions have $14.2M invested in Metagenomi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more capital invested

Capital invested by funds: $10.4M → $14.2M (+$3.79M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4.62% less ownership

Funds ownership: 20.61% → 15.99% (-4.6%)

16% less funds holding

Funds holding: 69 → 58 (-11)

45% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 22

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

Holders
58
Holders Change
-11
Holders Change %
-15.94%
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
12
Reduced
22
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$393K
2
BCM
Bridgeway Capital Management
Texas
+$197K
3
Walleye Capital
Walleye Capital
New York
+$145K
4
JP Morgan Chase
JP Morgan Chase
New York
+$124K
5
Man Group
Man Group
United Kingdom
+$107K

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$1.4M
2
TCM
Tang Capital Management
California
-$349K
3
UBS Group
UBS Group
Switzerland
-$194K
4
AQR Capital Management
AQR Capital Management
Connecticut
-$191K
5
Goldman Sachs
Goldman Sachs
New York
-$161K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$1K +$1.25K +615 New
RWM
52
Rialto Wealth Management
New York
$723 – – –
PD
53
Point72 (DIFC)
United Arab Emirates
$318 – – –
LFG
54
Larson Financial Group
Missouri
$119 -$154 -76 -60%
AAP
55
Arax Advisory Partners
Colorado
$71 +$61 +30 New
Optiver Holding
56
Optiver Holding
Netherlands
$43 +$37 +18 New
Barclays
57
Barclays
United Kingdom
$7 – – –
Norges Bank
58
Norges Bank
Norway
– -$373K -252,310 Closed
AQR Capital Management
59
AQR Capital Management
Connecticut
– -$191K -129,055 Closed
Goldman Sachs
60
Goldman Sachs
New York
– -$161K -108,596 Closed
Susquehanna International Group
61
Susquehanna International Group
Pennsylvania
– -$107K -72,587 Closed
Citadel Advisors
62
Citadel Advisors
Florida
– -$89.7K -60,624 Closed
Squarepoint
63
Squarepoint
New York
– -$56.4K -38,126 Closed
JG
64
Jain Global
New York
– -$42.4K -28,645 Closed
Brown Advisory
65
Brown Advisory
Maryland
– -$37K -25,006 Closed
VF
66
Virtu Financial
New York
– -$28K -19,008 Closed
SG Americas Securities
67
SG Americas Securities
New York
– -$28K -18,711 Closed
Verition Fund Management
68
Verition Fund Management
Connecticut
– -$20.6K -13,892 Closed
Prudential Financial
69
Prudential Financial
New Jersey
– -$19.8K -13,400 Closed
CFM
70
Catalyst Funds Management
Australia
– -$18.8K -12,700 Closed
TRCT
71
Tower Research Capital (TRC)
New York
– -$18.3K -12,375 Closed
GSC
72
Ground Swell Capital
South Carolina
– -$18.1K -12,198 Closed
SWM
73
Spire Wealth Management
Virginia
– -$9.62K -6,500 Closed
Deutsche Bank
74
Deutsche Bank
Germany
– -$7.92K -5,349 Closed
Carson Wealth (CWM LLC)
75
Carson Wealth (CWM LLC)
Nebraska
– -$3.3K -1,626 -98%
1 2
3
4

MGX Hedge Fund Activity: Q3 2025 in Review

58 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q3 2025, worth a combined $14.2M — up 37% from $10.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of MGX and 9 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 12 added.

The largest buyer was Two Sigma Investments, adding an estimated $393K. The largest seller was Pura Vida Investments, cutting an estimated $1.4M.

  • 58 institutional investors held Metagenomi Therapeutics (MGX) as of Q3 2025, down from 69 in Q2 2025.
  • Funds reported $14.2M of Metagenomi Therapeutics stock for Q3 2025, up 37% quarter-over-quarter.
  • 9 funds opened new Metagenomi Therapeutics positions in Q3 2025 and 19 closed out, a net change of -10 holders.
  • The largest Metagenomi Therapeutics buyer in Q3 2025 was Two Sigma Investments, an estimated $393K added.
  • The largest Metagenomi Therapeutics seller in Q3 2025 was Pura Vida Investments, an estimated $1.4M sold.

Based on aggregated 13F filings for Q3 2025.